Yarlagadda S. Babu's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 50,000 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on Nov. 14, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.42 per share. | 14 Nov 2022 | 50,000 | 330,056 (0%) | 0% | 1.4 | 71,000 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2022 | 50,000 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2022 | 50,000 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.42 per share. | 14 Nov 2022 | 50,000 | 280,056 (0%) | 0% | 1.4 | 71,000 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Sale of securities on an exchange or to another person at price $ 13.88 per share. | 14 Nov 2022 | 31,515 | 298,541 (0%) | 0% | 13.9 | 437,428 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Sale of securities on an exchange or to another person at price $ 17.16 per share. | 07 Mar 2022 | 20,000 | 230,056 (0%) | 0% | 17.2 | 343,200 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 164,000 | 164,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 35,000 | 250,056 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 62,000 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 07 Dec 2021 | 62,000 | 245,156 (0%) | 0% | 4.7 | 293,260 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Chief Discovery Officer | Sale of securities on an exchange or to another person at price $ 12.20 per share. | 07 Dec 2021 | 30,100 | 215,056 (0%) | 0% | 12.2 | 367,220 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Senior VP - Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.15 per share. | 19 Feb 2021 | 50,000 | 205,587 (0%) | 0% | 4.2 | 207,500 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Senior VP - Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2021 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Senior VP - Drug Discovery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.53 per share. | 19 Feb 2021 | 22,431 | 183,156 (0%) | 0% | 11.5 | 258,629 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Senior VP - Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 280,000 | 280,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Yarlagadda S. Babu | Senior VP - Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2020 | 17,000 | 17,000 | - | - | Emp. Stock Option (Right to Buy) |